HIGHLIGHTS
- who: Min-long Chen et al. from the University of Toledo, United States have published the research work: HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review, in the Journal: (JOURNAL)
SUMMARY
With the development of anti-HER2 systemic treatments, patients with HER2-positive breast cancer achieve long-term survival benefits, which also increase the incidence of brain metastases (BMs). BC with central nervous system (CNS) metastases has been reported in 15%-25% of BC patients, and BMs occur in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.